Richard Holland studied chemistry at the University of Manchester (UK) where he gained an honours degree and a passion for the science of medicinal chemistry.
He continued his studies at the Institute of Cancer Research (London, UK) completing his PhD in combinatorial chemistry in the field of oncology, specifically looking for novel pharmaceutical agents with activity against a variety of newly discovered cancer targets.
Following this work he took a post-doctoral position at the Thrombosis Research Institute (London, UK) working on inhibitors of the coagulation cascade in particular Factor IIa and Factor IXa. Whilst at the TRI, a small private biotech company was created to commercialise their discoveries and this provided Richard with his first experience of small biotech and start-up companies.
In 2004, Richard immigrated to Canada, eventually becoming a citizen in 2008. He continued his work as a medicinal chemist at Neuromed Pharmaceuticals (which later become Zalicus pharmaceuticals). Neuromed was also an academic spin off company set up to create novel Calcium Channel blockers primarily with utility in neuropathic pain and inflammation but also in other central nervous system diseases such as epilepsy. At Neuromed, Richard became Associate director of medicinal chemistry, team leader and also project representative during a 2 year research collaboration with Merck Research Laboratories which at the time was the biggest biotechnology deal in Canadian history.
More recently Richard has moved to another local company, Arbutus biopharma, where he is actively involved in researching cures for Hepatitis B through siRNA and small molecules.
He has been involved in two projects that led to clinical candidates and has been involved with numerous IND applications.
While at Arbutus, Richard was approached by Alex to counsel on the creation of Rejuvenation. He was initially skeptical about the possible role of molecular hydrogen and hydrogen enriched water in promoting health and well being. However, after spending time reviewing the extensive literature and scientific articles published in respected and trusted peer review journals he became increasingly convinced about its therapeutic potential. Of particular interest and relevance in the context of his role as medicinal chemist at Arbutus was a study (in human’s) describing the possibility of using molecular hydrogen to treat Hepatitis B, a disease which affects approximately 350 million people world wide.
He brings his extensive experience in pharmaceutical research and chemistry to HRW Natural Health Products Inc., where he is committed to bringing the best products possible to the market to improve quality of life. He helped fine tune Rejuvenation’s unique formulation and he continually strives to innovate new cutting edge products.